Загрузка...
Bispecific antibodies in cancer immunotherapy
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publishing
2018-02-01
|
| Серии: | Therapeutic Advances in Vaccines and Immunotherapy |
| Online-ссылка: | https://doi.org/10.1177/2515135518763280 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|